The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more ...

Critical Reviews in Oncology/Hematology

Volumn 74, Issue SUPPL. 1, 2010, Pages S2-

  Gnant, Michael ^a   Eidtmann, Holger ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; GOSERELIN; LETROZOLE; TAMOXIFEN; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE DENSITY; BONE METASTASIS; BREAST CANCER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; JAW OSTEONECROSIS; KIDNEY FAILURE; OSTEOLYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTMENOPAUSE; REVIEW; SURVIVAL TIME;

EID: 77952309903     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(10)70003-2     Document Type: Review

References (21)

1. Winter MC, Holen I, Coleman RE Exploring the anti-tumor activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008, 34:453-475.
2. Santini D, Martini F, Fratto ME, et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009, 58:31-38.
3. Gnant M Onco Target Ther 2009, 2:95-104.
4. Meads MB, Hazlehurst LA, Dalton WS The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008, 14:2519-2526.
5. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008, 12:2007-2011.
6. Saarto T, Blomqvist C, Virkkunen P, Elomaa I Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001, 19:10-17.
7. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 2006, 8:R13.
8. Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 2008 Sep, 23(9):1435-1441.
9. Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T Zoledronic acid - a multiplicity of anti-cancer action. Curr Med Chem 2007, 14(20):2126-2135.
10. Alakangas A, Selander K, Mulari M, et al. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 2002, 70:40-47.
11. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
12. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:820-828.
13. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008, 9:840-849.
14. Eidtmann H, Bundred N, De Boer R, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving letrozole: 36 months follow-up of ZO-FAST. Presented at 31st San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, TX. Abstract 44.
15. Brufsky A, Bundred N, Coleman R, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008, 13:503-514.
16. Coleman RE Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 2006, 24(18 suppl):5s. Abstract 511.
17. Perez EA Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007, 18(suppl 8):26-35. viii.
18. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008, 112(5):1001-1010.
19. Paget S Secondary growth in cancer of breast. Lancet 1889, 571.
20. Coleman R, Gnant M New results from the use of bisphosphonates in cancer patients. Curr Opin Supp Palliat Care 2009, 3:213-218.
21. Mittal S, Mifflin R, Powell DW Cancer stem cells: the other face of Janus. Am J Med Sci 2009, 338:107-112.